Format

Send to

Choose Destination
J Clin Virol. 2015 Mar;64:160-73. doi: 10.1016/j.jcv.2014.08.030. Epub 2014 Oct 24.

Yellow fever.

Author information

1
Hookipa Biotech AG, Vienna, Austria; PaxVax Inc., Menlo Park Redwood City, CA, USA. Electronic address: tpmonath@gmail.com.
2
Department of Arbovirology and Hemorrhagic Fevers, National Reference Laboratory of Arboviruses, Instituto Evandro Chagas, Ministry of Health, Rodovia BR 316 Km 07, S/N, CEP 67030-000 Ananindeua, Brazil; National Institute of Science and Technology for Viral Hemorrhagic Fevers, Instituto Evandro Chagas, Ministry of Health, Rodovia BR 316 Km 07, S/N, CEP 67030-000 Ananindeua, Brazil; PAHO/WHO Collaborating Center for Arbovirus Research and Diagnostic Reference, Instituto Evandro Chagas, Ministry of Health, Rodovia BR 316 Km 07, S/N, CEP 67030-000 Ananindeua, Brazil; Pará State University, Belém, Pará, Brazil. Electronic address: pedrovasconcelos@iec.pa.gov.br.

Abstract

Yellow fever, a mosquito-borne flavivirus disease occurs in tropical areas of South America and Africa. It is a disease of major historical importance, but remains a threat to travelers to and residents of endemic areas despite the availability of an effective vaccine for nearly 70 years. An important aspect is the receptivity of many non-endemic areas to introduction and spread of yellow fever. This paper reviews the clinical aspects, pathogenesis, and epidemiology of yellow fever, with an emphasis on recent changes in the distribution and incidence of the disease. Recent knowledge about yellow fever 17D vaccine mechanism of action and safety are discussed.

KEYWORDS:

Epidemiology; Pathogenesis; Yellow fever

PMID:
25453327
DOI:
10.1016/j.jcv.2014.08.030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center